Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Ishares Msci Italy ETF (EWI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Ishares Msci Italy ETF — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while Ishares Msci Italy ETF trades at $56.06 (market cap $1.20B). The key difference: Dyne Therapeutics Inc. Common Stock is far larger — about 2.4× Ishares Msci Italy ETF's market cap, and Ishares Msci Italy ETF is trading nearer its 52-week high, Dyne Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Ishares Msci Italy ETF for 55 Days on average.
| DYN | EWI | |
|---|---|---|
Market Cap | $2.86B | $1.20B |
Volume | 3,341,579 | 332,777 |
Sector | Health | Broad Market / Factor |
52-Week High | $26.78 | $63.35 |
52-Week Low | $14.60 | $50.47 |
Typical Hold Time | 0 Days | 55 Days |
Enterprise Value | $2.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
EWI, the iShares MSCI Italy ETF, trades at $56.66 with a 0.87% daily gain. Technical indicators show a bearish trend with moving averages signaling strong selling pressure, though oscillators are neutral with RSI levels suggesting potential oversold conditions. The ETF offers concentrated exposure to Italian financials, utilities, and industrials, benefiting from sector consolidation and EU-supported infrastructure investments.
The outlook remains cautious due to eurozone economic pressures and ECB tightening, but EWI provides strategic access to Italy's banking and infrastructure investment cycle. Key risks include eurozone business confidence declines and energy price volatility. Analyst sentiment is mixed with technical weakness offset by long-term structural opportunities in Italian markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Ishares Msci Italy ETF
EWI is a country-specific ETF that tracks the performance of the Italian equity market. It provides targeted access to large and mid-sized companies in Italy, with a heavy focus on the financial sector and holdings like UniCredit and Intesa Sanpaolo.
Read more on EWI →
